Spark Biomedical Publishes Pilot Trial Results for Menstrual Health
Spark Biomedical, parent company of OhmBody, has published the first peer-reviewed human trial evaluating transcutaneous auricular neurostimulation (tAN) for menstrual health. The study, featured in Frontiers in Medicine, shows significant improvements in heavy menstrual bleeding (HMB) and related symptoms. The pilot study included 16 participants, both women with von Willebrand Disease (VWD) and those with unexplained HMB. Participants who used OhmBody’s wearable tAN device daily during menstruation experienced an average 50% reduction in menstrual blood loss and shorter periods by nearly 20%. They also reported improvements in cramping, fatigue, and overall quality of life. By engaging the body’s natural nervous system through the vagus and trigeminal nerves, tAN offers a non-invasive, drug-free approach to managing heavy menstrual bleeding—highlighting a promising new option for women whose symptoms are not effectively treated by existing therapies.
Spark Biomedical Publishes Pilot Trial Results for Menstrual Health